Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Siemens SARS-CoV-2 testing portfolio detects omicron

January 2022—Siemens Healthineers announced that the company’s SARS-CoV-2 tests are designed to detect the omicron variant. The company evaluated the potential impact of the variant on the Clinitest Rapid COVID-19 antigen test; the FTD SARS-CoV-2 assay, a PCR test; and the Atellica IM/Advia Centaur SARS-CoV-2 antigen assay (CoV2Ag). To assess the potential impact of the Clinitest rapid test and the CoV2Ag assay, Siemens’ R&D team analyzed the sequence data of the omicron variant nucleocapsid protein, which demonstrated greater than 98 percent sequence homology of the nucleocapsid protein to other SARS-CoV-2 variants. The Clinitest Rapid COVID-19 Antigen Self-Test has a sensitivity of 97.25 percent and a specificity of 100 percent compared with a PCR, or nucleic acid-detection method, and provides results in 15 minutes.

Bio-Rad adds SARS-CoV-2 S gene delta-kappa variants control

January 2022—Bio-Rad Laboratories launched its Exact Diagnostics SARS-CoV-2 S Gene Delta-Kappa Variants Control for research testing. The control includes lineages B.1.617.1, B.1.617.2 (AY sublineages), and B.1.617.3. The product is an addition to the company’s SARS-CoV-2 S gene variants controls alpha, beta, epsilon, and gamma, which were released in August.

Streck launches QC for sepsis

January 2022—Streck announced the availability of its MDx-Chex for BCID2 quality control, designed to meet the standards for verifying the performance of sample-to-result molecular tests for sepsis.

LumiraDx, Audere offer at-home self-collection kit

January 2022—LumiraDx announced a partnership with digital health nonprofit Audere to offer a COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA Star Complete assay to process self-collected samples. SARS-CoV-2 RNA Star Complete has received FDA emergency use authorization for use by authorized laboratories. Laboratories using SARS-CoV-2 RNA Star Complete will be able to integrate Audere’s HealthPulse@home into their systems.

Co-Diagnostics to acquire Idaho Molecular, Advanced Conceptions

January 2022—Co-Diagnostics has entered into definitive agreements with Idaho Molecular and Advanced Conceptions in which both companies will become wholly owned subsidiaries of Co-Dx. Salt Lake City–based Co-Dx has been working with Idaho Molecular and Advanced Conceptions on the development of Co-Dx’s at-home, point-of-care diagnostic device. The transactions will provide Co-Dx with existing and future assets and intellectual property related to the platform.

Roche launches Cobas 5800 molecular Dx system in CE markets

January 2022—Roche launched its Cobas 5800 system in countries accepting the CE mark. The real-time PCR molecular testing solution is built to offer a fully automated workflow that encompasses sample supply, transfer and preparation, amplification and detection, result calculation, and delivery to the laboratory information system. The single module enables a walkaway time of up to eight hours.

Seegene PCR test IDs omicron, VOCs in one tube

January 2022—Seegene unveiled the Novaplex SARS-CoV-2 Variants VII assay for research use only. The assay identifies positive COVID-19 cases and distinguishes between alpha, beta, gamma, delta, and omicron and its stealth version. The RT-PCR test targets five analytes including the RdRP gene and three omicron S-gene mutations, E484A, N501Y, HV69/70 deletion. It also targets endogenous internal controls, which serve as a control to verify specimen validity.

Postmortem oral fluid toxicology testing

January 2022—Death investigators are tasked with the responsibility of providing irrefutable and accurate determinations in the cause and manner of death in a timely fashion for ongoing investigations. Outcomes of any death may be revealed by the specimens submitted for toxicology analysis. The conundrum of ample opinions is that there is no “one size fits all” when selecting appropriate specimens. Human nature tends to rely on traditional approaches for the collection, processing, and reporting of results because it’s easier to stay status quo. However, with drug overdose deaths increasing, reports are further delayed, causing an influx of backlogged cases. To assist with these issues, our laboratory developed an economical, time-efficient, safe, and less-invasive collection method that delivers real-time results within 24 to 48 hours, accelerating the autopsy process and the ability to close cases expeditiously.

Hardy Diagnostics releases HardyChrom Candida plus auris

December 2021—Hardy Diagnostics has released its Hardy­Chrom Candida plus auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species. This medium allows for the identification of C. albicans, C. tropicalis, and C. krusei, and the presumptive identification of C. glabrata.

Bio-Rad launches enhanced Liquichek diabetes control

December 2021—Bio-Rad Laboratories launched an enhanced version of its Liquichek Diabetes Control. The liquid, human whole-blood–based control comes in three levels to address the HbA1c precision monitoring needs of a wide range of test methods.

MARKETPLACE

TRENDING